Global Artificial Intelligence in Drug Discovery and Development Market Strategic Research Report

Scope of the Report

The global Artificial Intelligence in Drug Discovery and Development market size is predicted to grow from US$ 2,844 million in 2025 to US$ 19,030 million in 2032; it is expected to grow at a CAGR of 31.8% from 2026 to 2032.

As an important force driving a new round of scientific and technological revolution, artificial intelligence has been of national strategic importance. Many governments introduces polices and increase capital investment to support AI companies. The Digital Europe plan adopted by the European Union will allocate €9.2 billion on high-tech investments, such as supercomputing, artificial intelligence, and network security. In order to maintain its leading position, the United States will increase its investment in artificial intelligence research and development in non-defense fields, from US$1.6 billion to US$1.7 billion in 2022. According to the latest data released by IDC, global artificial intelligence revenue was US$432.8 billion in 2022, a year-on-year increase of 19.6%, including software, hardware and services.

China and the United States are two leaders in AI industry. On the AI 100 list (2022) released by CB Insights, the number of companies in the United States ranks first, with more than 70 companies, followed by the United Kingdom, with 8 companies on the list. China and Canada both holds 5 companies on the list. According to data from the China Academy of Information and Communications Technology, the scale of China"s core artificial intelligence industry reached ¥508 billion in 2022, a year-on-year increase of 18%. From 2013 to November 2022, the cumulative number of patent applications for artificial intelligence inventions in the world reached 729,000, and the cumulative number of applications in China reached 389,000, accounting for 53.4%. However, the Global Artificial Intelligence Innovation Index Report 2021 released by the China Institute of Scientific and Technological Information shows that the overall strength of the United States is still far ahead. The number of artificial intelligence companies in the United States is about 4,670, while China has only 880. China"s data center is less than 1/20 of that of the United States.

This report presents a comprehensive overview of the global Artificial Intelligence in Drug Discovery and Development market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Hardware
• Software
• Service

Segment by Application

• Early Drug Discovery
• Preclinical Phase
• Clinical Phase
• Regulatory Approval

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Artificial Intelligence in Drug Discovery and Development market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Early Drug Discovery, Preclinical Phase, Clinical Phase evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact